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The herbicide cyanazine is a synthetic s-tri-
azine (along with atrazine and simazine) that
has been widely used to control broadleaf
weeds and grasses in agricultural crops. It is
applied as a preemergent herbicide once dur-
ing the growing season to control weeds in
corn, sorghum, cotton, barley, wheat, oil rape
seed, sugar cane, and potatoes. Highest use of
cyanazine has been in the corn-growing states
of the Midwest (Snedeker and Clark 1998). 
In the 1990s, cyanazine ranked as the ﬁfth
most commonly used herbicide in the United
States, with an estimated 32 million pounds
applied annually [U.S. Environmental
Protection Agency (EPA) 2004]. Human
exposure to cyanazine occurs in farming and
pesticide manufacturing and through contami-
nated groundwater (Barbash et al. 2001;
Ritter 1990) and agricultural runoff (Hansen
et al. 2001). The most common application
methods for cyanazine are in solution by
ground boom or as a pellet, with the most
common route of exposure to humans being
dermal. There is little evidence to suggest that
applicators are exposed to cyanazine via
inhalation with recommended methods of use
(U.S. EPA 1994). 
The U.S. EPA classified cyanazine as a
restricted use pesticide based on the detection
of cyanazine in ground and surface water (i.e.,
restricted use pesticides may only be used by
pesticide applicators certified by the state
authorities), and as a Group C, possible
human carcinogen based on the increased
incidence of mammary tumors in rats from
dietary cyanazine exposure of 25 or 50 ppm
(Bogdanffy MS, unpublished data) and the
possible mutagenic effect of cyanazine in
mice lymphoma cells (Jannasch M, Sawin V,
unpublished data). The manufacturer pro-
posed to gradually phase out cyanazine pro-
duction and use in the United States by
1999. The U.S. EPA Office of Pesticide
Programs cancelled cyanazine product regis-
trations and prohibited the sale and use of
existing stocks of cyanazine after 30
September 2002 (U.S. EPA 1996). Although
cyanazine is banned in the United States, it is
still used in various African nations (e.g.,
South Africa, Niger), Asia and the Pacific
Region (e.g., Australia, India, New Zealand,
the Philippines), Europe (e.g., Hungary,
Portugal, United Kingdom), Central Asia,
Canada, and South America (Pesticide Action
Network 2004).
Despite its worldwide use, studies on the
health effects from cyanazine exposure speciﬁ-
cally have been limited and results have been
mixed. Studies suggest that cyanazine could be
mutagenic (Jannasch M, Sawin V, unpub-
lished data) and induce marginal DNA dam-
age in vivo in mouse leukocytes administered
high doses intraperitoneally (Tennant et al.
2001), but others showed no effects in human
lymphocytes and rat bone marrow (Hrelia
et al. 1994). Cyanazine exposure was associ-
ated with the formation of mammary-gland
tumors in Sprague-Dawley rats (Bogdanffy
MS, unpublished data); mechanism of action
studies suggest that tumor formation is medi-
ated through a prolactin mechanism thought
to be of low relevance to the development of
human breast cancer (Bogdanffy et al. 2000).
However, a new study suggests that prolactin
may play a larger role in the development of
human breast cancer, more than previously
thought (Harvey 2005). 
Epidemiologic studies evaluating cancer
risks associated with the triazine herbicide class
and with other triazines, such as atrazine, have
been conducted (Alavanja et al. 2003; Brown
et al. 1990; Donna et al. 1989; Hoar et al.
1986; Hopenhayn-Rich et al. 2002; Kettles
et al. 1997; MacLennan et al. 2002, 2003;
Rusiecki et al. 2004; Young et al. 2004). Using
a job exposure matrix to estimate cumulative
exposure to triazine herbicides, Young et al.
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BACKGROUND: Cyanazine is a common pesticide used frequently in the United States during the
1980s and 1990s. Animal and human studies have suggested that triazines may be carcinogenic, but
results have been mixed. We evaluated cancer incidence in cyanazine-exposed pesticide applicators
among the 57,311 licensed pesticide applicators in the Agricultural Health Study (AHS). 
METHODS: We obtained detailed pesticide exposure information from a self-administered ques-
tionnaire completed at enrollment (1993–1997). Cancer incidence was followed through January
2002. Over half of cyanazine-exposed applicators had ≥ 6 years of exposure at enrollment, and
approximately 85% had begun using cyanazine before the 1990s. We used adjusted Poisson
regression to calculate rate ratios (RRs) and 95% conﬁdence intervals (CIs) of multiple cancer sites
among cyanazine-exposed applicators. We calculated ptrend values, and all statistical tests were two-
sided. Two exposure metrics were used: tertiles of lifetime days of exposure (LD) and intensity-
weighted LD.
RESULTS: A total of 20,824 cancer-free AHS applicators reported ever using cyanazine at enroll-
ment. Cancer incidence comparisons between applicators with the lowest cyanazine exposure and
those with the highest exposure yielded the following for the LD metric: all cancers, RR = 0.99
(95% CI, 0.80–1.24); prostate cancer, RR = 1.23 (95% CI, 0.87–1.70); all lymphohematopoietic
cancers, RR = 0.92 (95% CI, 0.50–1.72); non-Hodgkin lymphoma, RR = 1.25 (95% CI,
0.47–3.35); lung cancer, RR = 0.52 (95% CI, 0.22–1.25).
CONCLUSIONS: We did not ﬁnd any clear, consistent associations between cyanazine exposure and
any cancer analyzed. The number of sites was small for certain cancers, limiting any conclusion
with regard to ovarian, breast, and some other cancers. 
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herbicide. Environ Health Perspect 114:1248–1252 (2006). doi:10.1289/ehp.8997 available via
http://dx.doi.org/ [Online 31 May 2006](2004) found nonstatistically significant
increased odds ratios (ORs) associated with
quartiles of triazine herbicide exposure and
ovarian cancer [ORhigh = 1.34; 95% conﬁdence
interval (CI), 0.42–4.28]. A case–control study
found a signiﬁcant increase of ovarian cancer
[rate ratio (RR) = 2.7)] in triazine-exposed
female farmers (Donna et al. 1989). Ecologic
studies have shown a statistically significant
increased risk of breast cancer with increasing
triazine exposure (Kettles et al. 1997).
However, another ecologic study did not ﬁnd
an association between atrazine exposure and
breast cancer (Hopenhayn-Rich et al. 2002).
In triazine-exposed manufacturing workers,
greater than expected numbers of prostate,
bladder, oral cavity, and lymphohematopoietic
cancers were observed (MacLennan et al.
2002), but only prostate cancer was statisti-
cally signiﬁcant [standardized incidence ratio
(SIR) = 3.94 (95% CI, 1.28–9.20)]; all the
prostate cancer cases detected were early-stage
cancers, and the excess may have been due to a
prostate-antigen screening program conducted
at the facility (MacLennan et al. 2002). A
mortality study of the same manufacturing
worker population also found an increased
standardized mortality ratio (SMR) for non-
Hodgkin lymphoma (NHL) [SMR = 3.72
(95% CI, 1.01–9.52)] (MacLennan et al.
2003). Reported use of several individual pes-
ticides, including atrazine, in combination
with other pesticides was associated with
increased NHL incidence in a case–control
study in the Midwest (De Roos et al. 2003).
No association was found between
atrazine exposure and prostate cancer in a
study of the Agricultural Health Study (AHS)
cohort (Alavanja et al. 2003). Another recent
study of the AHS cohort did not find any
clear association between use of atrazine and
any cancer analyzed, including prostate cancer
(highest exposure quartile: RR = 0.88; 95%
CI, 0.63–1.23) and non-Hodgkin lymphoma
(highest exposure quartile: RR = 1.61; 95%
CI, 0.62–4.16) (Rusiecki et al. 2004). In
case–control studies, atrazine or triazine herbi-
cide use was also not associated with Hodgkin
disease (Hoar et al. 1986), leukemia (Brown
et al. 1990), multiple myeloma (Burmeister
1990), soft-tissue sarcoma (Hoar et al. 1986),
or colon cancer (Hoar et al. 1985).
Given the previously high use of cyanazine
in the United States, continued use in other
countries, and the suggestive but incomplete
data on human cancer risk, we used data from
the AHS cohort to conduct the largest prospec-
tive evaluation of cyanazine exposure and can-
cer incidence to date. Because this cohort
consisted of mostly male applicators and
because the numbers of cancer cases were small
for certain cancer sites of a priori interest, i.e.,
breast (n = 2), ovarian (n = 1), and oral cavity
(n = 18), we focused this investigation on
cancers for which there were at least 30 cancer
cases exposed to cyanazine to ensure reason-
able statistical power: prostate, all lympho-
hematopoietic, NHL, lung, colon, and all
cancers combined.
Methods
Cohort enrollment and follow-up. The AHS is
a prospective study of 57,311 private and com-
mercial licensed pesticide applicators who live
in Iowa and North Carolina (Alavanja et al.
1996) and were recruited between 1993 and
1997 (Alavanja et al. 1999). Members of the
AHS cohort were matched to cancer registry
ﬁles in both states for case identiﬁcation and to
state death registries and the National Death
Index to ascertain vital status. Incident cancers
were identified for the time period from the
date of enrollment through December 2002
and were coded according to the International
Classiﬁcation of Diseases for Oncology, 2nd edi-
tion (ICD-O-2) (World Health Organization
1990). Cohort members who were alive were
identiﬁed through current address records of
the Internal Revenue Service (address informa-
tion only), motor vehicle registration ofﬁces,
and pesticide license registries of the state agri-
cultural departments. Person-year accumula-
tion for cancer incidence of individuals who
had moved from Iowa or North Carolina was
censored in the year they departed, although
they were still followed up for mortality. The
mean time of follow-up was 7.5 years. More
than half of the applicators exposed to
cyanazine had ≥ 6 years of exposure at the
time of enrollment, and approximately 85%
of the applicators had begun using cyanazine
before 1990. All participants provided verbal
informed consent, and the protocol was
approved by all appropriate institutional
review boards.
Exposure assessment. Study participants
were asked to complete a self-administered
questionnaire at the time of enrollment, which
collected comprehensive exposure data on 22
pesticides, information on ever/never use for
28 additional pesticides, use of personal pro-
tective equipment, pesticide application meth-
ods, pesticide mixing, equipment repair,
lifestyle factors, cancer history, and other
demographic factors. Applicators completing
this questionnaire were given additional take-
home questionnaires, which sought additional
information on occupational exposures (com-
mercial and private applicator questionnaire
data version P1REL0310.02 and cancer reg-
istry/mortality data version AHSREL0412.01
were used in this analysis). The questionnaires
may be accessed at http://www.aghealth.org/
questionnaires.html (National Institutes of
Health 2004). 
We constructed two cumulative lifetime
cyanazine exposure metrics for this analysis,
each categorized into tertiles, based on the
tertile levels among all cancer cases. The life-
time days of exposure (LD) calculation (years
of use × number of days used per year),
resulted in the following tertiles: 1–16, 17–56,
and ≥ 57 lifetime days. The second exposure
metric, intensity-weighted LD (IWLD) (years
of use × number of days used per year × inten-
sity level), resulted in the following tertiles:
1–83, 84–314.35, and ≥ 315.35 IWLD. To
determine the number of days in an average
year and the number of lifetime years, respec-
tively, we asked each participant who indi-
cated ever exposure to cyanazine to choose
from a range of days per year and years
applied. The midpoint of the indicated range
for both years applied and days per year
applied were used to calculate the exposure
metrics. We estimated intensity levels using
questionnaire data from enrollment and mea-
surement data from the published pesticide
exposure literature, as follows: intensity level =
[(mixing status + application method + equip-
ment repair status) × personal protective equip-
ment use] (Dosemeci et al. 2002). We
investigated those cancer sites for which there
were at least 30 cases and 9 cases in each expo-
sure category. We split the upper tertile at the
median whenever it was possible to further
investigate possible exposure–response trends.
Statistical analysis. Prevalent cancer cases
identiﬁed at or before enrollment (n = 1,075)
and applicators who did not provide informa-
tion on cyanazine use (n = 5,436) or were miss-
ing exposure information (n = 483) were
excluded from this analysis, leaving 50,317
applicators. Our analyses included primary,
incident cancer cases only. To examine internal
exposure–response relationships, we used
Poisson regression to estimate and compare
RRs and 95% CIs associated with tertiles of
LD (RRld) and IWLD (RRiwld). We used two
groups for reference: those reporting no use of
cyanazine and those in the lowest tertile of life-
time days of use. 
RRs were adjusted for age at enrollment (as
a continuous variable), sex, race (white/non-
white), education level [high school/general
equivalency diploma (GED) or lower, beyond
high school], alcohol consumption at enroll-
ment (ever, never), family history of cancer in
ﬁrst-degree relatives (yes/no), state of residence
(Iowa/North Carolina), and cigarette smoking
history [never/low/high: median value of pack-
years (12) among smokers classified low and
high categories of smokers]. For each of the
cumulative exposure metrics, LD and IWLD,
tests for trend were carried out using the mid-
points of each tertile entered into the model as
a continuous variable; all statistical tests were
two-sided. Potential confounding from expo-
sure to other pesticides was controlled by
adjusting for the number of days of any pesti-
cide use and exposure to the ﬁve most highly
correlated pesticides: metolachlor, alachlor,
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imazethapyr, and triﬂuralin. These ﬁve pesti-
cides were identified from the 50 pesticides
assessed in the AHS, based on either the
strength of the correlation coefficient for
IWLD (highest r = 0.60, lowest r = 0.53) or
the strength of association for ever/never
comparisons between cyanazine and each of
the 28 pesticides with ever/never data only. In
the final models of the regression analyses,
exposure to five highly correlated pesticides
was categorized as ever/never use of the
respective pesticide. 
Results
Table 1 presents the selected characteristics of
the applicators in the AHS. Among the
50,800 subjects with complete exposure
information, 20,341 reported ever having
used cyanazine. The cohort comprised mostly
white, male, private applicators with relatively
low smoking rates; in both the exposed and
nonexposed groups, about half had never
smoked. The exposed and nonexposed groups
were similar in respect to most baseline char-
acteristics; however, the low exposed group
was more similar to the higher exposed group
than the nonexposed group in state of resi-
dence, corn production, and exposure to the
ﬁve most highly correlated pesticides. 
The Poisson regression RRs for selected
cancers among cyanazine-exposed applicators,
using the lowest tertile as the referent, are pre-
sented in Table 2. We split the top tertiles of
exposure for all cancers, all lymphohemato-
poietic cancers, NHL, and prostate cancer,
and results were not different (data not
shown). We found no evidence of an associa-
tion for all cancers combined. Prostate cancer
was the most frequent cancer in the cyanazine-
exposed cohort (n = 258). Prostate cancer
showed a slight excess among the exposed for
LD (RR = 1.23; 95% CI, 0.87–1.70) and
IWLD (RR = 1.15; 95% CI, 0.83–1.58), and
a statistically significant rate of 1.39 was
observed in the medium tertile for IWLD.
However, no evidence of a statistically signiﬁ-
cant exposure–response trend was seen. When
subjects were stratiﬁed into those with a family
history of prostate cancer and those without,
there was no evidence that cyanazine use was
associated with prostate cancer in either of the
groups. 
For all lymphohematopoietic cancers (RR =
0.92; 95% CI, 0.50–1.72) and colon cancer
(RR = 0.83; 95% CI, 0.39–1.77), there were
slight deﬁcits in the highest exposure group for
lifetime days. For NHL, a small, nonstatisti-
cally signiﬁcant increased risk for IWLD (RR =
1.43; 95% CI, 0.61–3.37) was observed; how-
ever, we found no exposure–response associa-
tion after splitting the third tertile. For lung
cancer, there was a slight, nonstatistically sig-
niﬁcant decrease in estimates with increasing
cyanazine use. No interaction between smok-
ing history and lung cancer occurred in our
data (data not shown).
Where nonexposed persons were used as
the referent, there was a statistically signiﬁcant
decreased risk associated with all exposure cate-
gories for LD (highest tertile: RR = 0.84; 95%
CI, 0.70–0.99) for all cancers combined. The
ptrend for IWLD for all cancers (p = 0.02) was
also statistically signiﬁcant (lowest tertile: RR =
0.82; 95% CI, 0.76–1.04; medium tertile: RR
= 0.88; 95% CI, 0.70–0.97; highest tertile: RR
= 0.79; 95% CI, 0.67–0.93). Using the non-
exposed group as the referent, we found no evi-
dence of a statistically signiﬁcant increased risk
or association with cyanazine exposure for
prostate, all lymphohematopoietic, NHL,
colon, and lung cancers. 
Discussion
We found no clear and consistent associations
between the incidence of any cancers analyzed
(i.e., prostate, all lymphohematopoietic, NHL,
colon, and lung cancers) using LD and IWLD
as exposure metrics. Overall cancer risk pat-
terns among exposed individuals were similar
regardless of the referent group used or the
exposure metric employed. In our study, we
had limited power to detect a signiﬁcant dif-
ference in risk for a number of cancer sites but
had larger numbers to investigate the risk of
prostate cancer with cyanazine exposure. Our
Lynch et al.
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Table 1. Selected characteristics of applicators by cyanazine exposure in the AHS based on 1993–1997
enrollment data [no. (%)].
Nonexposed Lowest exposed Highest exposed
Characteristics (n = 29,976) (n = 5,710)a (n = 14,631)b
Age (years)
< 40 10,693 (35.7) 1,707 (29.9) 4,468 (30.5)
40–49 7,794 (26) 1,749 (30.6) 4,787 (32.7)
50–59 5,848 (19.5) 1,219 (21.4) 3,131 (21.4)
≥ 60 5,640 (18.8) 1,035 (18.1) 2,245 (15.3)
Sex
Male 28,814 (96.1) 5,662 (99.2) 14,537 (99.4)
Female 1,162 (3.9) 48 (0.8) 94 (0.6)
Race
White 28,997 (96.7) 5,645 (98.9) 14,428 (98.6)
Nonwhite 895 (3) 50 (0.9) 170 (1.2) 
Missing 84 (0.3) 15 (0.2) 33 (0.2)
State of residence
Iowa 16,167 (53.9) 4,896 (85.7) 13,048 (89.2)
North Carolina 13,809 (46.1) 814 (14.3) 1,583 (10.8)
Applicator typec
Private 27,279 (91) 5,491 (96.2) 12,909 (88.2)
Commercial 2,697 (9) 219 (3.8) 1,722 (11.8)
Smoking history
Never 15,436 (51.5) 3,217 (56.3) 8,212 (56.1)
Low (< 12 pack-years)  6,399 (21.3) 1,276 (22.4) 3,268 (22.3)
High (≥ 12 pack-years) 6,916 (23.1) 1,086 (19) 2,821 (19.3)
Missing 1,225 (4.1) 131 (2.3) 330 (2.3)
Alcohol consumption
No 10,632 (35.5) 1,446 (25.3) 3,365 (23)
Yes 18,808 (62.7) 4,210 (73.7) 11,127 (76.1)
Missing 536 (1.8) 54 (0.95) 139 (0.95)
Educational level
≤ High school/GED 17,223 (57.5) 3,075 (53.9) 8,165 (55.8)
> High school 12,664 (42.2) 2,626 (46) 6,451 (44.1)
Missing 89 (0.3) 9 (0.16) 15 (0.1)
Family history of cancerd
No 17,243 (57.5) 3,047 (53.4) 8,010 (54.7)
Yes 10,654 (35.5) 2,379 (41.7) 5,962 (40.7)
Missing 2,079 (6.9) 284 (4.9) 659 (4.5)
Corn production
No 11,960 (39.9) 726 (12.7) 2,347 (16)
Yes 18,016 (60.1) 4,984 (87.3) 12,284 (84)
Ever exposure to ﬁve most highly correlated with cyanazine
Metolachlor 9,736 (32.5)e 3,476 (60.9)f 9,362 (64)g
EPTC 2,972 (9.8)e 1,618 (28.3)f 5,412 (37)g
Alachlor 10,922 (36.4)e 3,930 (68.8)f 10,668 (72.9)g
Imazethapyr 8,600 (28.7)e 3,256 (57.0)f 8,939 (61.1)g
Triﬂuralin 10,927 (36.5)e 3,840 (60.9)f 10,516 (71.9)g
aFirst tertile of LD (years of use × days of use per year). bSecond and third tertiles of LD (years of use × days of use per
year). cPrivate applicators are primarily individual farmers; commercial are professional pesticide applicators. dFirst-
degree relatives. eEver exposed to indicated chemical but not to cyanazine (thus, numbers in columns do not sum to
100%). fEver exposed to indicated chemical and in lowest tertile of cyanazine exposure (thus, numbers in columns do not
sum to 100%). gEver exposed to indicated chemical and in the highest two tertiles of cyanazine exposure (thus, numbers
in columns do not sum to 100%).study did not support the observed excess of
prostate cancer risk in a Louisiana plant man-
ufacturing triazine pesticides observed by
MacLennan et al. (2002) [SIR = 394 (95%
CI, 128–902)]. MacLennan et al. (2002) sug-
gest this association may have occurred
because prostate speciﬁc antigen screening was
carried out frequently among the study cohort
compared with the referent population. For
prostate cancer, a nonstatistically significant
increased risk among cyanazine-exposed appli-
cators was noted when using low exposed as
the referent group. However, this pattern was
not observed, and the RRs were not elevated
for prostate cancer when the nonexposed
group was used as the referent. There was no
consistent monotonic trend when the low
exposed group was used the referent. This lack
of consistency mitigates the possibility of an
association between cyanazine and prostate
cancer. A previous investigation of prostate
cancer in the AHS reported by Alavanja et al.
(2003) also did not ﬁnd a statistically signiﬁ-
cant association between the triazine herbi-
cide, atrazine, and prostate cancer. 
We found no evidence of a statistically
significant association between cyanazine
exposure and all lymphohematopoietic can-
cers combined, NHL, or colon cancer. In a
prospective cohort study of triazine herbicide
manufacturing workers, MacLennan et al.
(2002) found a nonsigniﬁcant increased SIR
for all lymphatic and hematopoietic cancers
(n = 7; 4.4 expected) and NHL (n = 3; 2.3
expected). A mortality study based on the
same population found nonsignificant
increased mortality ratios for NHL (n = 4; 1.1
expected); however, the study did not have
statistical power to assess trends in rates by
years worked and years since first hire
(MacLennan et al. 2003). Case–control stud-
ies found no association with NHL and
cyanazine exposure (De Roos et al. 2003) or
between colon cancer and triazine herbicide
exposure (Burmiester 1990).
For lung cancer there were nonsigniﬁcant
decreased RRs with increasing tertiles of LD
and IWLD for both referent groups. Because
neither the risk estimates nor the tests for
trend were statistically significant, and
because we had no a priori hypothesis sug-
gesting this trend, this may be a chance ﬁnd-
ing. Undetected residual confounding by
factors such as diet, exercise, or another envi-
ronmental exposure are unlikely to explain
these observations, because these factors are
not associated with cyanazine exposure. 
Lower risks of lung cancer were seen among
textile workers exposed to endotoxins in the
textile dust, despite smoking habits of the work-
ers (Levin et al. 1987). Agricultural pesticide
applicators can be exposed to endotoxins from
hay, grain, and animals. However, in our analy-
ses, endotoxin exposure does not appear to
account for the negative association between
cyanazine exposure and lung cancer (data not
shown), because there was not an association
between lung cancer and any measure of farm
exposure.
The AHS has several important strengths.
It is the largest study to date of pesticide appli-
cators exposed to cyanazine. Because compre-
hensive questionnaire data were used to
quantify cyanazine exposure levels, we were
able to provide greater discrimination between
potential high and low exposures to cyanazine.
The AHS has information on many potential
cancer risk factors and can control for impor-
tant confounders. It also controls for potential
biases. Recall bias is minimized because expo-
sure information was collected before cancer
diagnosis. Two control groups—low exposed
pesticide applicators and nonexposed applica-
tors—were used in this study to verify study
results. In general, farmers provide reliable
information and considerable detail regarding
their pesticide history (Blair and Zahm 1993;
Blair et al. 1997, 2002; Hoppin et al. 2002).
There is a lack of evidence for substantial
selection bias in the AHS; the responses on the
enrollment questionnaire of farmers who com-
pleted and returned the take-home question-
naire were remarkably similar to the responses
on the enrollment questionnaire of farmers
who did not return the take-home question-
naire (Tarone et al. 1997). 
Certain limitations of our data set reduce
the number and kinds of inferences we can
make regarding cyanazine and its association
with specific cancers. Although the AHS
cohort is large and many participants reported
cyanazine use, the small numbers of female
applicators and the small numbers of some
cancers limited our conclusions about certain
cancers at this time. The average age of the
applicators in our cohort is 56 years. The
observational power of the AHS will increase
markedly in the next few years as the cohort
continues to age. 
Most of the cyanazine pesticide applica-
tors were white males (99%), limiting our
ability to analyze female cancers of particular
interest including breast and ovarian cancers
(Bogdanffy MS, unpublished data; Donna
et al. 1989; Kettles et al. 1997; Young et al.
2004). However, in a study by Engel et al.
(2005), cyanazine exposure was not associated
with increased breast cancer risk in wives of
private applicators in the AHS who either
personally used cyanazine or whose husbands
used cyanazine. 
Despite some limitations, our prospective
study of cancer incidence among cyanazine-
exposed pesticide applicators was unlike other
studies, because we could evaluate cancer risks
associated with exposure to cyanazine, speciﬁ-
cally for all cancers, prostate, all lympho-
hematopoietic, NHL, colon, and lung cancers,
The Agricultural Health Study: cyanazine and cancer incidence
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Table 2. RRs (95% CIs) for selected cancersa by LD and IWLD to cyanazineb using low exposure as the
referent.
LD IWLD
Cancer site/tertile cut pointsc No.d RR (95%CI)e ptrend
f No.d RR (95% CI)g ptrend
f
All cancers 
1–16 174 1.00 (referent) 198 1.00 (referent)
17–56 256 1.04 (0.86–1.27) 203 1.07 (0.88–1.30)
≥ 57 180 0.99 (0.80–1.24) 0.79 206 0.94 (0.77–1.15) 0.35
Prostate
1–16 67 1.00 (referent) 74 1.00 (referent)
17–56 115 1.22 (0.89–1.65) 98 1.39 (1.03–1.88)*
≥ 57 76 1.23 (0.87–1.70) 0.43 85 1.15 (0.83–1.58) 0.93
All lymphohematopoietic
1–16 22 1.00 (referent) 25 1.00 (referent)
17–56 30 0.98 (0.56–1.70) 21 0.87 (0.49–1.56)
≥ 57 22 0.92 (0.50–1.72) 0.80 26 0.92 (0.52–1.62) 0.88
NHL 
1–16 9 1.00 (referent) 10 1.00 (referent)
17–56 18 1.56 (0.69–3.50) 12 1.30 (0.56–3.00)
≥ 57 9 1.25 (0.47–3.35) 0.97 13 1.43 (0.61–3.37) 0.49
Colon
1–16 16 1.00 (referent) 20 1.00 (referent)
17–56 16 0.69 (0.35–1.39) 13 0.69 (0.34–1.39)
≥ 57 15 0.83 (0.39–1.77) 0.96 14 0.57 (0.27–1.17) 0.21
Lung
1–16 15 1.00 (referent) 16 1.00 (referent)
17–56 15 0.69 (0.33–1.44) 12 0.76 (0.36–1.63)
≥ 57 9 0.52 (0.22–1.25) 0.25 11 0.56 (0.25–1.26) 0.12
aCancers for which there were at least 30 exposed cases. RRs were adjusted for age, race, sex, alcohol consumption,
smoking status, education level, family history of cancer, state of residence, and use of the ﬁve most highly correlated
pesticides with cyanazine. bTotal number exposed to cyanazine without precancer history prior to enrollment and missing
exposure information = 20,341. cTertiles of LD. Units for IWLD are not displayed in this table because they have intrinsic
value. dNumber of cancer-speciﬁc case patients exposed to cyanazine (total and for each tertile of exposure). eRRld = RR
of LD (i.e., years of use × number of days of use per year). fp-Values were two-sided. gRRiwld = RR of IWLD (i.e., years of
use × number of days of use per year × intensity index). *Indicates statistical signiﬁcance. Lynch et al.
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while adjusting for lifestyle factors, common
pesticide exposures, and other confounders.
No clear, statistically signiﬁcant increased risk
of any of the specific cancers was observed
among the 607 cyanazine-exposed cancer
cases. The findings of this cyanazine study
complement those found in the atrazine study
(Rusiecki et al. 2004). Further detail on cancer
risk, including the risk of the less frequent
cancers (e.g., ovarian, breast), will be possible
with continued follow-up of the AHS cohort. 
REFERENCES
Alavanja MC, Samanic C, Dosemeci M, Lubin J, Tarone R, Lynch
CF, et al. 2003. Use of agricultural pesticides and prostate
cancer risk in the Agricultural Health Study cohort. Am J
Epidemiol 157:800–814.
Alavanja MC, Sandler DP, McDonnell CJ, Lynch CF, Pennybacker
M, Zahm SH, et al. 1999. Characteristics of pesticide use in a
pesticide applicator cohort; the Agricultural Health Study.
Environ Res 90:172–179.
Alavanja MC, Sandler DP, McMaster SB, Zahm SH, McDonnell
CJ, Lynch CF, et al. 1996. The Agricultural Health Study.
Environ Health Perspect 104:362–369.
Barbash JE, Thelin GP, Kolpin DW, Gilliom RJ. 2001. Major her-
bicides in ground water: results from the National Water-
Quality Assessment. J Environ Qual 30:831–845.
Blair A, Stewart PA, Kross B, Ogilvie L, Burmeister LF, Ward MH,
et al. 1997. Comparison of two techniques to obtain informa-
tion on pesticide use from Iowa farmers by interview.
J Agric Saf Health 3:229–236.
Blair A, Tarone R, Sandler D, Lynch C, Rowland A, Wintersteen
W, et al. 2002. The reliability of reporting on lifestyle and
agricultural factors by a sample of participants in the
Agricultural Health Study from Iowa. Epidemiology
13(1):94–99.
Blair A, Zahm SH. 1993. Patterns of pesticide use among farmers:
implications for epidemiological research. Epidemiology
4(1):55–62.
Bogdanffy MS, O’Connor JC, Hansen JF, Gaddamidi V, Van Pelt
CS, Green JW, et al. 2000. Chronic toxicity and oncogenicity
bioassay in rats with the chloro-s-triazine herbicide
cyanazine. J Toxicol Environ Health 60(8):567–586.
Brown LM, Blair A, Gibson R, Everett GD, Cantor KP, Schuman
LM, et al. 1990. Pesticide exposures and other agricultural
risk factors for leukemia among men in Iowa and Minnesota.
Cancer Res 50:6585–6591.
Burmeister LF. 1990. Cancer in Iowa farmers: recent results.
Am J Ind Med 18: 295–301.
De Roos AJ, Zahm SH, Cantor KP, Weisenburger DD, Holmes
FF, Burmeister LF, et al. 2003. Integrative assessment of
multiple pesticides as risk factors for non-Hodgkin’s lym-
phoma among men. Occup Environ Med 60(9):E11.
Donna A, Crosignani P, Robutti F, Betta PG, Bocca R, Mariani N,
et al. 1989. Triazine herbicides and ovarian epithelial neo-
plasms. Scand J Work Environ Health 15:47–53.
Dosemeci M, Alavanja MCR, Rowland AS, Mage D, Zahm SH,
Rothman N, et al. 2002. A semi-quantitative approach for
estimating exposure to pesticides in the Agricultural
Health Study. Ann Occup Hyg 46(2):245–260.
Engel LS, Hill DA, Hoppin JA, Lubin JH, Lynch CF, Pierce J,
et al. 2005. Pesticide use and breast cancer risk among
farmers’ wives in the Agricultural Health Study. Am J
Epidemiol 161(2):121–135.
Hansen NC, Moncrief JF, Gupta SC, Capel PD, Olness AE. 2001.
Herbicide banding and tillage system interactions on
runoff losses of alachlor and cyanazine. J Environ Qual
30(6):2120–2126.
Harvey PW. 2005. Human relevance of rodent prolactin-induced
non-genotoxic mammary carcinogenesis: prolactin
involvement in human breast cancer and signiﬁcance for
toxicology risk assessments. J Appl Toxicol 25(3):179–183.
Hoar SK, Blair A, Holmes FF, Boysen C, Robel RJ. 1985.
Herbicides and colon cancer. Lancet 1:1277–1278.
Hoar SK, Blair A, Holmes FF, Boysen CD, Robel RJ, Hoover R,
et al. 1986. Agricultural herbicide use and risk of lym-
phoma and soft-tissue sarcoma. JAMA 256:1141–1147.
Hopenhayn-Rich C, Stump ML, Browning SR. 2002. Regional
assessment of atrazine exposure and incidence of breast
and ovarian cancers in Kentucky. Arch Environ Contam
Toxicol 42(1):127–136. 
Hoppin JA, Yucel F, Dosemeci M, Sandler DP. 2002. Accuracy
of self-reported pesticide use duration information from
licensed pesticide applicators in the Agricultural Health
Study. J Expo Anal Environ Epidemiol 12:313–318.
Hrelia P, Vigagni F, Maffei F, Morotti M, Colacci A, Perocco P,
et al. 1994. Genetic safety evaluation of pesticides in dif-
ferent short-term tests. Mutat Res 321(4):219–228.
Kettles MK, Browning SR, Prince TS, Horstman SW. 1997.
Triazine herbicide exposure and breast cancer incidence:
an ecologic study of Kentucky counties. Environ Health
Perspect 105:1222–1227.
Levin LI, Gao YT, Blot WJ, Zheng W, Fraumeni JF Jr. 1987.
Decreased risk of lung cancer in the cotton textile industry
of Shanghai. Cancer Res 47(21):5777–5781.
MacLennan PA, Delzell E, Sathiakumar N, Myers SL. 2003.
Mortality among triazine herbicide manufacturing work-
ers. J Toxicol Environ Health 66:501–517.
MacLennan PA, Delzell E, Sathiakumar N, Myers SL, Cheng H,
Grizzle W, et al. 2002. Cancer incidence among triazine
herbicide manufacturing workers. J Occup Environ Med
44:1048–1058.
National Institutes of Health. 2004. Agricultural Health Study
Homepage. Bethesda, MD:National Institutes of Health.
Available: http://www.aghealth.org [accessed 25 September
2004]. 
Pesticide Action Network. 2004. PAN Pesticides Database—
Pesticide Registration Status. Available: http://www.
pesticideinfo.org/Detail_ChemReg.jsp?Rec_Id=PC33516
[accessed 1 October 2004].
Ritter WF. 1990. Pesticide contamination of ground water in the
United States—a review. J Environ Sci 25(1):1–29.
Rusiecki JA, De Roos A, Lee WJ, Dosemeci M, Lubin JH,
Hoppin JA, et al. 2004. Cancer incidence among pesticide
applicators exposed to atrazine in the Agricultural Health
Study. J Natl Cancer Inst 96(18):1375–1382.
Snedeker SM, Clark H. 1998. Critical evaluation of cyanazine’s
breast cancer risk. Program on Breast Cancer and
Environmental Risk Factors in New York State (BCERF).
Available: http://envirocancer.cornell.edu/FactSheet/
Pesticide/fs17.cyanazine.cfm [accessed 1 January 2005].
Tarone RE, Alavanja MCR, Zahm SH, Lubin JH, Sandler DP,
McMaster MP, et al. 1997. The Agricultural Health Study:
factors affecting completion and return of self-adminis-
tered questionnaires in a large prospective cohort study of
pesticide applicators. Am J Ind Med 31:233–242.
Tennant AH, Peng B, Kligerman AD. 2001. Genotoxicity studies
of three triazine herbicides: in vivo studies using the alka-
line single gel (SCG) assay. Mutat Res 493(1-2):1–10.
U.S. EPA (U.S. Environmental Protection Agency). 1994.
Atrazine, simazine and cyanazine: notice of initiation of
special review. Fed Reg 59:60412–60443. Available:
http://www.epa.gov/fedrgstr/EPA-PEST/1994/November/
Day-23/pr-54.html [accessed 18 October 2004].
U.S. EPA (U.S. Environmental Protection Agency). 1996.
Cyanazine: notice of ﬁnal determination of terminate special
review of cyanazine; notice of voluntary cancellation and
cancellation order of cyanazine product registrations. Fed
Reg 61:39024–39029.
U.S. EPA (U.S. Environmental Protection Agency). 2004. Federal
Insecticide, Fungicide, and Rodenticide Act (FIFRA).
Available: http://www.epa.gov/opp00001/regulating/
ﬁfra.pdf [accessed 2 January 2005]. 
World Health Organization. 1990. International Statistical
Classification of Disease for Oncology. 2nd ed.
Geneva:World Health Organization.
Young HA, Mill PK, Riordan R, Cress R. 2004. Use of a crop and
job specific exposure matrix for estimating cumulative
exposure to triazine herbicides among females in a case-
control study in the Central Valley of California. Occup
Environ Med 61(11):945–951.